These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 6465106)

  • 21. Blood dyscrasias induced by psychotropic drugs.
    Stübner S; Grohmann R; Engel R; Bandelow B; Ludwig WD; Wagner G; Müller-Oerlinghausen B; Möller HJ; Hippius H; Rüther E
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S70-8. PubMed ID: 15052517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postmarketing surveillance versus clinical trials: which benefits the patient?
    Lawson DH
    Cardiology; 1994; 85 Suppl 1():18-23. PubMed ID: 7743530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept.
    Feltelius N; Fored CM; Blomqvist P; Bertilsson L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L;
    Ann Rheum Dis; 2005 Feb; 64(2):246-52. PubMed ID: 15208177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The incidence of microbial keratitis among wearers of a 30-day silicone hydrogel extended-wear contact lens.
    Schein OD; McNally JJ; Katz J; Chalmers RL; Tielsch JM; Alfonso E; Bullimore M; O'Day D; Shovlin J
    Ophthalmology; 2005 Dec; 112(12):2172-9. PubMed ID: 16325711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
    Farahani P; Levine M; Gaebel K; Thabane L
    Can J Clin Pharmacol; 2005; 12(3):e254-63. PubMed ID: 16278497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis.
    Rutter MD; Saunders BP; Wilkinson KH; Rumbles S; Schofield G; Kamm MA; Williams CB; Price AB; Talbot IC; Forbes A
    Gastroenterology; 2006 Apr; 130(4):1030-8. PubMed ID: 16618396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cimetidine: adverse reactions and acute toxicity.
    Sawyer D; Conner CS; Scalley R
    Am J Hosp Pharm; 1981 Feb; 38(2):188-97. PubMed ID: 7011006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of the late effects surveillance system (LESS).
    Paulides M; Kremers A; Stöhr W; Bielack S; Jürgens H; Treuner J; Beck JD; Langer T;
    Pediatr Blood Cancer; 2006 Apr; 46(4):489-95. PubMed ID: 16333817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chymodiactin postmarketing surveillance. Demographic and adverse experience data in 29,075 patients.
    Agre K; Wilson RR; Brim M; McDermott DJ
    Spine (Phila Pa 1976); 1984; 9(5):479-85. PubMed ID: 6387953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Postmarketing surveillance of the safety of cimetidine: mortality during second, third, and fourth years of follow up.
    Colin-Jones DG; Langman MJ; Lawson DH; Vessey MP
    Br Med J (Clin Res Ed); 1985 Oct; 291(6502):1084-8. PubMed ID: 3931805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postmarketing surveillance of the safety of cimetidine: 12 month mortality report.
    Colin-Jones DG; Langman MJ; Lawson DH; Vessey MP
    Br Med J (Clin Res Ed); 1983 May; 286(6379):1713-6. PubMed ID: 6405946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medical education reduces inappropriate use of cimetidine in a teaching hospital.
    Gardiner DC; Champion MC; Sweet D; Kozakowski K; Wielgosz A
    CMAJ; 1985 Sep; 133(5):408-11. PubMed ID: 4027806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cimetidine postmarket outpatient surveillance program.
    Crawley JA; Gardner JS; Lee JG
    JAMA; 1981 Apr; 245(14):1409. PubMed ID: 7009900
    [No Abstract]   [Full Text] [Related]  

  • 34. Postmarketing surveillance of the safety of cimetidine: 10 year mortality report.
    Colin-Jones DG; Langman MJ; Lawson DH; Logan RF; Paterson KR; Vessey MP
    Gut; 1992 Sep; 33(9):1280-4. PubMed ID: 1358768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Depression not associated with cimetidine.
    Antell LA; Murabito AS; Karlstadt RG
    Pa Med; 1989 Nov; 92(11):26, 28. PubMed ID: 2636871
    [No Abstract]   [Full Text] [Related]  

  • 36. Review: post-marketing surveillance of the safety of cimetidine--the problems of data interpretation.
    Jones DG; Langman MJ; Lawson DH; Vessey MP
    Aliment Pharmacol Ther; 1987 Jun; 1(3):167-77. PubMed ID: 2979221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Drug surveillance. Monitoring the collateral effects of drugs in the post-marketing phase: cimetidine. I].
    Mariani L; Minora T
    Clin Ter; 1984 Apr; 109(1):3-17. PubMed ID: 6233077
    [No Abstract]   [Full Text] [Related]  

  • 38. Intensive hospital monitoring study of intravenous cimetidine.
    Porter JB; Beard K; Walker AM; Lawson DH; Jick H; Kellaway GS
    Arch Intern Med; 1986 Nov; 146(11):2237-9. PubMed ID: 3778056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gynaecomastia, galactorrhoea and impotence--the uncommon side effects of cimetidine therapy.
    Jauhari J
    J Assoc Physicians India; 1987 Jun; 35(6):462. PubMed ID: 3654561
    [No Abstract]   [Full Text] [Related]  

  • 40. Perspectives on the future of postmarket vaccine safety surveillance and evaluation.
    Ball R
    Expert Rev Vaccines; 2014 Apr; 13(4):455-62. PubMed ID: 24606417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.